Neurotransmitter transporters

NTHU Unveils Ray of Hope for Improving Dementia Treatment

Retrieved on: 
Tuesday, October 6, 2020
Health, Other Health, Clinical trials, Research, Science, Biotechnology, Membrane proteins, Branches of biology, Proteins, Solute carrier family, Integral membrane proteins, Neurotransmitter transporters, Transport proteins, Ion transporter, Cotransporter

The teams research finding has been published in the August issue of Science Advances.

Key Points: 
  • The teams research finding has been published in the August issue of Science Advances.
  • Human phosphate transporter (hPiT) is an important membrane protein for transporting phosphate and sodium ions into brain cells.
  • Sun said that analyzing the human phosphate transporter and locating the site of the patients variants are important in finding a treatment for brain calcification.
  • The first step in analyzing the molecular structure of membrane protein is to cultivate the membrane protein crystal.

AIkido Pharma Announces Publication of Results from Sponsored Research at Wake Forest University

Retrieved on: 
Thursday, May 28, 2020
Proteins, Neurotransmitter transporters, Solute carrier family, Transport proteins, Deoxycytidine kinase, Equilibrative nucleoside transporter, Nucleoside transporter, Nucleoside analogue, DCK, Deoxycytidine, Kinase

The paper documents the results from the company's sponsored research at Wake Forest University.

Key Points: 
  • The paper documents the results from the company's sponsored research at Wake Forest University.
  • Nucleoside analogs are subject to resistance mechanisms including downregulation of equilibrative nucleoside transporter (ENT1) and deoxycytidine kinase (dCK).
  • Anthony Hayes, CEO of AIkido stated, "Wake Forest University is a world-class research facility and an outstanding partner for AIkido.
  • AIkido was initially formed in 1967 and is a biotechnology company with a diverse portfolio of small-molecule anti-cancer therapeutics.

China Approves AUSTEDO® For Treating Chorea Associated with Huntington's Disease and Tardive Dyskinesia in Adults

Retrieved on: 
Monday, May 18, 2020
Health, Pharmaceutical, Branches of biology, Organ systems, Nervous system, Neurological disorders, Amphetamine, Huntington's disease, Tardive dyskinesia, Neurotransmitter transporters, Deutetrabenazine, Teva Pharmaceutical Industries, Vesicular monoamine transporter, Movement disorders, Huntington's Disease, Tardive Dyskinesia, AUSTEDO® (deutetrabenazine), Teva

This is the second approval and expected launch in China of a Teva specialty medicine, following the recent launch of TREANDA.

Key Points: 
  • This is the second approval and expected launch in China of a Teva specialty medicine, following the recent launch of TREANDA.
  • The approval of AUSTEDO in China is an exciting milestone for Teva," said Gianfranco Nazzi, Executive Vice President, International Markets, at Teva.
  • Tardive dyskinesia is a movement disorder characterized by repetitive and uncontrollable movements of the tongue, lips, face, trunk and extremities.
  • AUSTEDO is a vesicular monoamine transporter 2 (VMAT2) inhibitor approved by the U.S. Food and Drug Administration for the treatment of tardive dyskinesia in adults and for the treatment of chorea associated with Huntingtons disease.

Neurocrine Biosciences to Present Data from its Movement Disorder Portfolio on the American Academy of Neurology Science Highlights Platform

Retrieved on: 
Wednesday, May 13, 2020
Branches of biology, Amphetamine, Biogenic amines, Neurotransmitter transporters, Receptors, Signal transduction, Neurocrine Biosciences, Neurocrine, Tardive dyskinesia, Dopamine, Vesicular monoamine transporter 2, Vesicular monoamine transporter

SAN DIEGO, May 13, 2020 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that multiple scientific presentations and abstracts from its movement disorder programs will be available on the 2020 American Academy of Neurology (AAN) Annual Meeting Science Highlights Platform beginning May 18, 2020.

Key Points: 
  • SAN DIEGO, May 13, 2020 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that multiple scientific presentations and abstracts from its movement disorder programs will be available on the 2020 American Academy of Neurology (AAN) Annual Meeting Science Highlights Platform beginning May 18, 2020.
  • "We look forward to presenting data from our movement disorder programs for tardive dyskinesia and Parkinson's disease at the AAN Science Highlights platform," said Eiry W. Roberts, M.D., Chief Medical Officer at Neurocrine Biosciences.
  • In patients with TD, these treatments are thought to result in irregular dopamine signaling in a region of the brain that controls movement.
  • VMAT2 is a protein in the brain that packages neurotransmitters, such as dopamine, for transport and release from presynaptic neurons.

Neurocrine Biosciences to Present Data on INGREZZA® (valbenazine) for Tardive Dyskinesia; Opicapone and VY-AADC for Parkinson's Disease, at the 2019 International Congress of Parkinson's Disease and Movement Disorders®

Retrieved on: 
Tuesday, September 17, 2019
Branches of biology, Amphetamine, Neurotransmitter transporters, Biogenic amines, Receptors, Signal transduction, Vesicular monoamine transporter 2, Vesicular monoamine transporter, Dopamine, Neurotransmitter, Neuron, Parkinson's disease

The data will be presented at the 2019 International Congress of Parkinson's Disease and Movement Disorders in Nice, France, Sept. 22-26, 2019.

Key Points: 
  • The data will be presented at the 2019 International Congress of Parkinson's Disease and Movement Disorders in Nice, France, Sept. 22-26, 2019.
  • "These data add to our understanding of these debilitating movement disorders that can place a substantial burden on the lives of patients."
  • In patients with TD, these treatments are thought to result in irregular dopamine signaling in a region of the brain that controls movement.
  • VMAT2 is a protein in the brain that packages neurotransmitters, such as dopamine, for transport and release in presynaptic neurons.

Neurocrine Biosciences Provides Preliminary Fourth Quarter and Full-Year 2018 Net Product Sales Results and 2019 Program Milestones

Retrieved on: 
Sunday, January 6, 2019
Neuroscience, Biochemistry, Biology, Amphetamine, Biogenic amines, Neurotransmitter transporters, Receptors, Signal transduction, Neurocrine Biosciences, Valbenazine, Vesicular monoamine transporter 2, Vesicular monoamine transporter

"Our fourth quarter and 2018 results reflect the dedication of our team in educating healthcare providers about tardive dyskinesia and the benefit INGREZZA can bring to patients.

Key Points: 
  • "Our fourth quarter and 2018 results reflect the dedication of our team in educating healthcare providers about tardive dyskinesia and the benefit INGREZZA can bring to patients.
  • VMAT2 is a protein in the brain that packages neurotransmitters, such as dopamine, for transport and release in presynaptic neurons.
  • Neurocrine Biosciences, a San Diego based biopharmaceutical company, is focused on developing treatments for neurological and endocrine related disorders.
  • Neurocrine disclaims any obligation to update the statements contained in this press release after the date hereof.